Advertisement

 

 

Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.

Blood cytokine concentrations of pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma patients.
Author Information (click to view)

Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W,


Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W, (click to view)

Knörr F, Damm-Welk C, Ruf S, Singh VK, Zimmermann M, Reiter A, Woessmann W,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Haematologica 2017 12 14() pii haematol.2017.177972
Abstract

Patients with anaplastic lymphoma kinase -positive anaplastic large cell lymphoma often present with B-symptoms or hemophagocytosis and generate an anti-tumor immune response. Specific serum cytokine levels or profiles may reflect the tumor burden, an unspecific immune stimulation by the tumor or differences in the strength of the patient’s anti-lymphoma immunity. We systematically correlated pre-treatment concentrations of 25 cytokines with clinical and biological characteristics in a well characterized cohort of 119 uniformly treated pediatric anaplastic large cell lymphoma patients. 15 anaplastic large cell lymphoma patients in remission and 11 low-stage B-cell lymphoma patients served as controls. Concentrations of IL-9, IL-10, IL-17a, HGF, sIL-2R, and sCD30 were significantly elevated in initial sera of patients as compared to both control groups, indicating an anaplastic large cell lymphoma-type cytokine signature. The levels of IL-6, IFN-ɣ, IP-10, and sIL-2R correlated with the stage, initial general condition, minimal disseminated disease, ALK-antibody titers, and the risk of relapse among ALK-positive anaplastic large cell lymphoma patients. Only IL-6 showed an independent prognostic value in multivariate analyses. Pre-treatment cytokine profiles in anaplastic large cell lymphoma patients reflect both a tumor-signature as well as tumor burden and differences in the strength of the patient’s immune response.

Submit a Comment

Your email address will not be published. Required fields are marked *

eighteen − seven =

[ HIDE/SHOW ]